Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTNMNASDAQ:CURROTCMKTS:FSDDFNASDAQ:HLVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTNMContineum Therapeutics$3.62+1.4%$4.57$3.35▼$22.00$94.69MN/A82,775 shs58,846 shsCURRCURRENC Group$0.60+4.3%$1.24$0.44▼$7.08$27.92M-0.172.15 million shs1.26 million shsFSDDFFSD Pharma$13.46+7.0%$8.16$3.43▼$68.66$102.03MN/A11,100 shs441,083 shsHLVXHilleVax$1.85-0.8%$1.75$1.34▼$15.60$92.51M0.78446,569 shs256,021 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTNMContineum Therapeutics0.00%+1.40%-11.71%-45.07%-76.37%CURRCURRENC Group0.00%+19.52%-57.45%-71.43%+59,999,900.00%FSDDFFSD Pharma0.00%+16.54%+97.94%+195.82%+4,386.67%HLVXHilleVax0.00%-0.81%-5.87%+5.43%-84.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTNMContineum Therapeutics2.3204 of 5 stars3.62.00.00.03.20.80.6CURRCURRENC GroupN/AN/AN/AN/AN/AN/AN/AN/AFSDDFFSD PharmaN/AN/AN/AN/AN/AN/AN/AN/AHLVXHilleVax2.4512 of 5 stars3.01.00.00.02.73.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTNMContineum Therapeutics 3.20Buy$22.50521.55% UpsideCURRCURRENC Group 3.50Strong Buy$3.50483.33% UpsideFSDDFFSD Pharma 0.00N/AN/AN/AHLVXHilleVax 2.00Hold$3.0062.60% UpsideCurrent Analyst Ratings BreakdownLatest CURR, HLVX, FSDDF, and CTNM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025CTNMContineum TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$25.00 ➝ $20.005/15/2025CTNMContineum TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$31.00 ➝ $31.003/31/2025HLVXHilleVaxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.003/13/2025CTNMContineum TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.003/7/2025CTNMContineum TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$25.00 ➝ $25.003/7/2025CTNMContineum TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$32.00 ➝ $16.003/5/2025CURRCURRENC GroupUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$3.503/5/2025CURRCURRENC GroupRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/5/2025CURRCURRENC GroupRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.50(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTNMContineum Therapeutics$50M1.87$0.57 per share6.35($3.72) per share-0.97CURRCURRENC Group$43.39M0.64N/AN/AN/A∞FSDDFFSD Pharma$70K1,457.53N/AN/AN/A∞HLVXHilleVaxN/AN/AN/AN/A$5.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTNMContineum Therapeutics$22.72M-$1.97N/AN/AN/AN/A-49.92%-20.52%8/12/2025 (Estimated)CURRCURRENC GroupN/AN/A0.00∞N/AN/AN/AN/A7/14/2025 (Estimated)FSDDFFSD Pharma-$17.52MN/A0.00∞N/AN/AN/AN/AN/AHLVXHilleVax-$123.57M-$2.15N/AN/AN/AN/A-67.27%-51.99%8/7/2025 (Estimated)Latest CURR, HLVX, FSDDF, and CTNM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025CURRCURRENC Group-$0.04-$0.13-$0.09-$0.13$10.50 million$10.06 million5/14/2025Q1 2025CTNMContineum Therapeutics-$0.56-$0.62-$0.06-$0.62$7.50 millionN/A5/8/2025Q1 2025HLVXHilleVax-$0.37-$0.12+$0.25-$0.12N/AN/A4/14/2025Q4 2024CURRCURRENC Group-$0.04-$0.70-$0.66-$0.70$10.50 million$11.07 million3/28/2025Q4 2024HLVXHilleVax-$0.33-$0.35-$0.02-$0.68N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTNMContineum TherapeuticsN/AN/AN/AN/AN/ACURRCURRENC GroupN/AN/AN/AN/AN/AFSDDFFSD PharmaN/AN/AN/AN/AN/AHLVXHilleVaxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTNMContineum TherapeuticsN/A37.0637.06CURRCURRENC GroupN/AN/AN/AFSDDFFSD PharmaN/A1.811.60HLVXHilleVaxN/A14.2514.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTNMContineum TherapeuticsN/ACURRCURRENC Group56.01%FSDDFFSD Pharma0.43%HLVXHilleVax86.42%Insider OwnershipCompanyInsider OwnershipCTNMContineum Therapeutics11.30%CURRCURRENC Group17.80%FSDDFFSD PharmaN/AHLVXHilleVax24.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTNMContineum Therapeutics3125.87 millionN/AN/ACURRCURRENC Group246.53 million38.25 millionN/AFSDDFFSD Pharma107.58 millionN/ANot OptionableHLVXHilleVax2050.14 million14.39 millionNot OptionableCURR, HLVX, FSDDF, and CTNM HeadlinesRecent News About These CompaniesBrokerages Set HilleVax, Inc. (NASDAQ:HLVX) PT at $3.00May 23, 2025 | americanbankingnews.comHilleVax, Inc. (NASDAQ:HLVX) is largely controlled by institutional shareholders who own 51% of the companyMay 22, 2025 | finance.yahoo.comHilleVax, Inc. (NASDAQ:HLVX) Given Average Rating of "Hold" by BrokeragesMay 22, 2025 | marketbeat.comStonepine Capital Management LLC Acquires New Stake in HilleVax, Inc. (NASDAQ:HLVX)May 20, 2025 | marketbeat.comLightspeed Management Company L.L.C. Buys Shares of 2,341,376 HilleVax, Inc. (NASDAQ:HLVX)May 14, 2025 | marketbeat.comHilleVax, Inc.: HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company ProgressMay 9, 2025 | finanznachrichten.deHilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company ProgressMay 8, 2025 | globenewswire.comJPMorgan Chase & Co. Acquires 193,124 Shares of HilleVax, Inc. (NASDAQ:HLVX)May 4, 2025 | marketbeat.comHilleVax (HLVX) to Release Earnings on ThursdayMay 3, 2025 | marketbeat.comSamsara BioCapital LLC Trims Stake in HilleVax, Inc. (NASDAQ:HLVX)May 2, 2025 | marketbeat.comHilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company ProgressMarch 28, 2025 | globenewswire.comHillevax CEO Robert Hershberg sells $48,661 in stockFebruary 12, 2025 | msn.comHillevax CFO Shane Maltbie sells $15,116 in stockFebruary 12, 2025 | msn.comHilleVax, Inc. Announces Workforce Reduction and Leadership ChangesDecember 5, 2024 | tipranks.comCautious Hold Rating on HilleVax, Inc: Balancing Strong Cash Reserves with Strategic UncertaintyNovember 12, 2024 | markets.businessinsider.comHilleVax Reports Q3 Financial Results Amid Strategic PlanningNovember 9, 2024 | markets.businessinsider.comHilleVax, Inc: Analyst Maintains Hold Rating Amid Vaccine Trial Setback and Strategic ShiftNovember 9, 2024 | markets.businessinsider.comHilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company ProgressNovember 8, 2024 | manilatimes.netWhat Makes HilleVax (HLVX) a New Buy StockOctober 14, 2024 | zacks.comHillevax Inc (HLVX) Stock: A Deeper Look at Its True PotentialSeptember 21, 2024 | bovnews.comHilleVax, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by HilleVax (HLVX)August 29, 2024 | accesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAmazon: Why The Great Comeback Rally Could Be About to BeginBy Sam Quirke | May 5, 2025View Amazon: Why The Great Comeback Rally Could Be About to BeginGlobalFoundries Stock Hits Bottom: Is a Rebound Coming?By Thomas Hughes | May 10, 2025View GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?By Nathan Reiff | May 10, 2025View Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?Bloomin’ Brands Stock Drops on Weak Guidance and Demand ConcernsBy Chris Markoch | May 9, 2025View Bloomin’ Brands Stock Drops on Weak Guidance and Demand ConcernsCURR, HLVX, FSDDF, and CTNM Company DescriptionsContineum Therapeutics NASDAQ:CTNM$3.62 +0.05 (+1.40%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$3.66 +0.04 (+1.10%) As of 07:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.CURRENC Group NASDAQ:CURR$0.60 +0.03 (+4.35%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$0.59 -0.01 (-1.33%) As of 08:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Currenc Group, Inc. engages in operating a fintech banking platform. It operates through the following segments: Remittance Services, Sales of Airtime, and Other Services. The company is headquartered in Singapore.FSD Pharma OTCMKTS:FSDDF$13.46 +0.88 (+7.00%) As of 05/30/2025FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz in 1994 and is headquartered in Cobourg, Canada.HilleVax NASDAQ:HLVX$1.84 -0.02 (-0.81%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.87 +0.03 (+1.36%) As of 07:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet Nike’s Amazon Expansion Could Signal a Turnaround in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
